Iressa (gefitinib): Questions and Answers on FDA Approval

Lung Cancer Slideshow

Questions and Answers on Iressa (gefitinib)

On June 17, 2005 the The Food and Drug Administration (FDA) has approved new labeling for gefitinib (Iressa) that limits use to patients with cancer who in the opinion of their treating physician, are currently benefiting, or have previously benefited, from Iressa treatment. In addition, AstraZeneca will distribute the drug under the Iressa Access Program. For more, please read the "Questions and Answers on Iressa's (gefitinib) New Labeling" article.


Iressa (gefitinib) is a groundbreaking new type of anti-cancer drug for people with the most common type of lung cancer. It is different from all prior chemotherapy. That is, Iressa works by uniquely blocking cellular enzymes that stimulate cell growth. So, in the future, look for the emergence of other (hopefully more effective) anti-cancer drugs that work at specific cellular or molecular sites.

With this approval by the Food and Drug Administration (FDA), patients having advanced lung cancer that is unresponsive to standard treatment now will have at least some treatment available to them. Credit the FDA for the relatively rapid availability of this drug. You see, Iressa was approved under the FDA's accelerated approval program. This program provides patients with serious disease earlier access to promising new drugs.

Leslie J. Schoenfield, M.D., Ph.D.
Medical Editor, MedicineNet.com


1. What is Iressa and how does it work?

Iressa is a new anticancer drug that inhibits an enzyme (tyrosine kinase) present in lung cancer cells, as well as other cancers and normal tissues, that appears to be important to the growth of cancer cells. The active ingredient in Iressa is gefitibib.

2. What is Iressa used to treat?

Iressa is used as a single agent for the treatment of non-small cell lung cancer (NSCLC) that has progressed after, or failed to respond to two other types of chemotherapy (drugs used to kill cancer cells). Iressa is not indicated as the first chemotherapy drug given (first-line therapy) for the treatment of NSCLC because it has shown no benefit in two large, well-controlled studies when used in that setting.

3. What is NSCLC?

Lung cancer is divided into two major classes: small cell lung cancer and non-small cell lung cancer. NSCLC is the most common type of lung cancer, accounting for almost 80% of lung cancers. There are five types of NSCLC, each of which has different kinds of cancer cells. The cancer cells of each type differ in size, shape, and chemical make-up, and grow and spread in different ways.

Quick GuideLung Cancer Symptoms, Stages, Treatment

Lung Cancer Symptoms, Stages, Treatment

4. Is Iressa taken alone or is it taken in combination with other chemotherapy drugs?

Iressa is taken alone, not with other chemotherapy.

5. Is Iressa a cure for NSCLC?

In the third line setting, i.e., after failure of two other agents, Iressa reduced tumor volume substantially in about 10% of people. There were no cures.

6. What is accelerated approval?

Accelerated approval is a program the FDA developed to make new drug products available for life threatening diseases when they appeared to provide a benefit over available therapy (which could mean there was no existing effective treatment). Under this program, Iressa is approved on the basis of early clinical study evidence (such as tumor shrinkage) suggesting that the drug is reasonably likely to have a valuable effect on survival or symptoms. The approval is granted on the condition that the manufacturer must continue testing to demonstrate that the drug indeed provides therapeutic benefit to the patient. If it does not, the FDA can withdraw the product from the market more easily than usual.

7. How many clinical trials were performed with Iressa and what did they show?

The study on which FDA based it approval included 216 patients 139 of whom had failed treatment with two other chemotherapy treatments. In this trial, approximately 10% of patients responded to Iressa with a decrease in tumor size.

The sponsor also presented to FDA the results of two large (about 1000 patients each) clinical studies with Iressa as initial therapy for lung cancer. In these studies all patients received, standard combination chemotherapy and were randomly given, in addition, either Iressa or a placebo. In these studies there was no effect of Iressa on survival, time to further growth of cancer, or on tumor size.

8. Is Iressa approved in other countries?

Yes, Iressa is approved in Japan.

9. Why was Iressa in the news shortly after approval in Japan?

There were reports of serious illness and deaths due to a lung disease associated with the use of Iressa in Japan. Based on these reports, the FDA requested more data from the sponsor and also discussed these reports with Japanese regulatory authorities. Since that time, the FDA has performed a comprehensive review of updated or new data from clinical studies and from the expanded access program, which included data from over 20,000 patients.

In addition, the FDA reviewed the Japanese clinical studies. The FDA determined that the rate of lung disease was about 2% in the Japanese experience, 1% in the two major U.S. clinical studies, and approximately 0.3% in the U.S. expanded access program. About 1/3 of the patients with lung disease died.

10. What is an expanded access program?

An expanded access program is a mechanism by which patients can receive an investigational drug such as Iressa, for a severe or life-threatening illness, even before FDA approval.

11. Does FDA believe that the same toxicity seen in Japan will occur in patients in the US?

Yes. This toxicity has been seen in the United States, although at a lower rate than in Japan. FDA believes the probable benefit of Iressa outweighs its risks in third line therapy for NSCLC.

12. What are other possible side effects of Iressa?

As discussed above, Iressa has been associated with reports of sometimes fatal lung toxicity. Reports have included inflammation of the lungs, such as interstitial pneumonia, pneumonitis, and alveolitis. These side effects may cause difficulty in breathing, with or without cough and fever, and may become severe in a very short period of time.

Other side effects reported in 10% of patients receiving 250 mg/day of Iressa were diarrhea, rash, acne, dry skin, nausea, and vomiting. The majority of these side effects did go away once the patient stopped taking Iressa.

13. How is Iressa taken?

Iressa is a tablet, taken once a day.

14. Where can I find more information on Iressa?

FDA Approves Iressa: Drug for Lung Cancer

For more about lung cancer, please read the Lung Cancer article and visit the Cancer Center.

Some of the above information has been provided with the kind permission of the FDA (www.fda.gov).


Quick GuideLung Cancer Symptoms, Stages, Treatment

Lung Cancer Symptoms, Stages, Treatment

Subscribe to MedicineNet's Cancer Report Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Reviewed on 6/20/2005

Health Solutions From Our Sponsors